PH 1 TRIAL EVALUATING MRG‐106, A MICRORNA‐155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T‐CELL LYMPHOMA (CTCL) PATIENTS

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 35; no. S2; pp. 275 - 276
Main Authors Querfeld, C., Foss, F.M., Porcu, P., Kim, Y.H., Pacheco, T., Haverkos, B., Halwani, A.S., DeSimone, J., William, B., Pinter‐Brown, L., Seto, A., Ruckman, J., Landry, M., Jackson, A.L., Dickinson, B., Sanseverino, M., Rodman, D., Rubin, P., Marshall, W.S.
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.06.2017
Subjects
Inhibitors
Intravenous administration
Lymphocytes T
Lymphoma
miRNA
Patients
pH effects
Ribonucleic acid
RNA
T-cell lymphoma
Online AccessGet full text

Cover

More Information
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2438_149